Background: The presence of Major Depressive Disorder (MDD) is often comorbid in patients with a variety of general medical conditions (GMCs) which could lead to less favorable outcomes. Objective: The goal of this analysis is to examine functional outcomes of QOL and functioning before and after antidepressant treatment among patients with MDD with and without GMCs. Methods: We performed a secondary analysis based on the STAR*D database. The analysis included two patient groups from the STAR*D trial: 1,198 patients comorbid with MDD and GMCs (MDD + GMC) and 1,082 patients with MDD and no GMCs (MDDnoGMC), as defined by the Cumulative Illness Rating Scale. We analyzed depressive symptom severity, functioning and quality of life (QOL) before and after level 1 treatment with citalopram. Results: At baseline, the MDD + GMC group had significantly lower QOL (p < 0.001) and functioning (p = 0.001) than the MDDnoGMC group, although depressive symptom severity was not significantly different. Following antidepressant treatment, QOL, functioning and depressive symptom severity significantly improved for both MDD + GMC and MDDnoGMC groups. However, patients with MDD + GMC were more likely to experience severe impairments in QOL in (56.8% vs. 43.5% for MDDnoGMC, p < 0.001) and functioning (42.5% vs. 29.3% for MDDnoGMC, p < 0.001) following treatment. The remission rate was significantly lower for MDD + GMC (30.6% vs. 41.1% for MDDnoGMC, p < 0.001). Conclusions: Our findings suggest that antidepressant treatment had a positive impact on patients with and without GMCs. However, those with GMCs experienced not only a lower remission rate, but also continued to experience more significantly severe impairments in QOL and functioning.
Background: The presence of Major Depressive Disorder (MDD) is often comorbid in patients with a variety of general medical conditions (GMCs) which could lead to less favorable outcomes. Objective: The goal of this analysis is to examine functional outcomes of QOL and functioning before and after antidepressant treatment among patients with MDD with and without GMCs. Methods: We performed a secondary analysis based on the STAR*D database. The analysis included two patient groups from the STAR*D trial: 1,198 patients comorbid with MDD and GMCs (MDD + GMC) and 1,082 patients with MDD and no GMCs (MDDnoGMC), as defined by the Cumulative Illness Rating Scale. We analyzed depressive symptom severity, functioning and quality of life (QOL) before and after level 1 treatment with citalopram. Results: At baseline, the MDD + GMC group had significantly lower QOL (p < 0.001) and functioning (p = 0.001) than the MDDnoGMC group, although depressive symptom severity was not significantly different. Following antidepressant treatment, QOL, functioning and depressive symptom severity significantly improved for both MDD + GMC and MDDnoGMC groups. However, patients with MDD + GMC were more likely to experience severe impairments in QOL in (56.8% vs. 43.5% for MDDnoGMC, p < 0.001) and functioning (42.5% vs. 29.3% for MDDnoGMC, p < 0.001) following treatment. The remission rate was significantly lower for MDD + GMC (30.6% vs. 41.1% for MDDnoGMC, p < 0.001). Conclusions: Our findings suggest that antidepressant treatment had a positive impact on patients with and without GMCs. However, those with GMCs experienced not only a lower remission rate, but also continued to experience more significantly severe impairments in QOL and functioning.
Entities:
Keywords:
comorbidity; functioning; major depression; medical condtions; quality of life
Authors: Lydia Chwastiak; Dawn M Ehde; Laura E Gibbons; Mark Sullivan; James D Bowen; George H Kraft Journal: Am J Psychiatry Date: 2002-11 Impact factor: 18.112
Authors: M P Luber; J P Hollenberg; P Williams-Russo; T N DiDomenico; B S Meyers; G S Alexopoulos; M E Charlson Journal: Int J Psychiatry Med Date: 2000 Impact factor: 1.210
Authors: Lea C Watson; Halle R Amick; Bradley N Gaynes; Kimberly A Brownley; Samruddhi Thaker; Meera Viswanathan; Daniel E Jonas Journal: J Prim Care Community Health Date: 2013-04-01
Authors: David Mataix-Cols; Amy J Cowley; Matthew Hankins; Andreas Schneider; Martin Bachofen; Mark Kenwright; Lina Gega; Rachel Cameron; Isaac M Marks Journal: Compr Psychiatry Date: 2005 May-Jun Impact factor: 3.735
Authors: Polly Hitchcock Noël; John W Williams; Jürgen Unützer; Jason Worchel; Shuko Lee; John Cornell; Wayne Katon; Linda H Harpole; Enid Hunkeler Journal: Ann Fam Med Date: 2004 Nov-Dec Impact factor: 5.166
Authors: Emma Morton; Erin E Michalak; Anthony Levitt; Robert D Levitan; Amy Cheung; Rachel Morehouse; Rajamannar Ramasubbu; Lakshmi N Yatham; Edwin M Tam; Raymond W Lam Journal: Can J Psychiatry Date: 2020-06-23 Impact factor: 4.356